-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2021, although the biomedical sector has not seen a significant recovery, the enthusiasm for institutional investigations continues
.
According to statistics, in the past week (December 1st to December 7th), at least 16 biomedical companies have been investigated by institutions, including Corfu Medical, Jincheng Pharmaceutical, Robust Medical, Xianju Pharmaceutical, Jincheng Pharmaceutical, and Panlong Pharmaceuticals, Yuekang Pharmaceuticals, etc.
, mainly focus on subdivisions such as chemical drugs, consumables, and APIs
.
Corfu Medical received surveys from 24 public funds including Wells Fargo Fund, Essence Fund, and Oriental Fund on December 5
.
From the survey records, the organization mainly focuses on the company's R&D layout and new product launch plans, the driving force of future performance growth, the future company's independent production enhancement plan, the current store opening situation and future store opening plans of the company
.
Among them, in terms of R&D layout and new product launch plans, the company stated that it currently has a number of key research projects, including the upgrading and iteration of existing key products and innovative research and development of cutting-edge technologies, and has formed an industrialization echelon
.
In the second half of this year, the company has successively launched a variety of blood glucose monitoring products, and will launch key new products such as ventilators and new oxygen generators next year
.
At the same time, the company's electric wheelchairs, mobility aids and other products will continue to realize independent production next year and expand production capacity.
With the help of the company's online and offline channel advantages, it is expected to achieve rapid growth in related categories
.
The domestic cryogenic storage giant Haier Biology has also attracted the attention of public funds
.
The company released a record sheet of investor relations activities on December 2 and accepted investigations from 64 institutions.
The institutions focused on the company's performance, overseas market conditions, and research and development systems
.
It is understood that Haier Bio-Bio has intensively received multiple batches of institutions since the disclosure of the 2021 third quarter report at the end of October.
From October 28 to mid-November, the company has disclosed 4 records of investor relations activities and the number of institutions received Nearly 300 companies, including many top public offerings such as E Fund, China Asset Management, and China Universal Fund, as well as many top private placements such as Gaoyi Assets and Kaifeng Investment
.
In November, the company got the attention of the industry due to the fact that more than 150 institutions got together in three days.
At that time, the institutions mainly focused on the company's Internet of Things solution business, overseas distribution network system construction, future planning and other main business development
.
Haier Biological, a biomedical cryogenic storage equipment giant, is currently committed to transforming into a biosafety solution provider
.
In addition, pharmaceutical companies such as Xianju Pharmaceutical, Jincheng Pharmaceutical, Panlong Pharmaceutical, and Yuekang Pharmaceutical have also received institutional surveys in the past week.
The number of surveyed institutions is 34 and 57 respectively
.
Among them, Xianju Pharmaceutical is a pharmaceutical company integrating raw materials and preparations.
The organization is very concerned about the impact of centralized procurement on the company’s future development.
The company stated in the research report that if the company’s products are included in centralized procurement, it will mainly be anesthetic muscle relaxation preparations.
The revenue side of the company will have an impact; the influence of the centralized procurement of cisatracurium has been reflected in the second quarter, and the company's cisatracurium API has been transformed from the original pure self-supplied to simultaneous external sales
.
The profit side is relatively controllable; Ropivacaine Hydrochloride Injection was shortlisted for the fifth batch of national centralized procurement, which is a good opportunity for the company, and its sales volume has shown a substantial increase; the application field of misoprostol tablets is small and specialized.
There are mainly three domestic manufacturers, and these three companies are also involved in centralized procurement.
The manufacturers are relatively fixed and the medications are stable
.
.
According to statistics, in the past week (December 1st to December 7th), at least 16 biomedical companies have been investigated by institutions, including Corfu Medical, Jincheng Pharmaceutical, Robust Medical, Xianju Pharmaceutical, Jincheng Pharmaceutical, and Panlong Pharmaceuticals, Yuekang Pharmaceuticals, etc.
, mainly focus on subdivisions such as chemical drugs, consumables, and APIs
.
Corfu Medical received surveys from 24 public funds including Wells Fargo Fund, Essence Fund, and Oriental Fund on December 5
.
From the survey records, the organization mainly focuses on the company's R&D layout and new product launch plans, the driving force of future performance growth, the future company's independent production enhancement plan, the current store opening situation and future store opening plans of the company
.
Among them, in terms of R&D layout and new product launch plans, the company stated that it currently has a number of key research projects, including the upgrading and iteration of existing key products and innovative research and development of cutting-edge technologies, and has formed an industrialization echelon
.
In the second half of this year, the company has successively launched a variety of blood glucose monitoring products, and will launch key new products such as ventilators and new oxygen generators next year
.
At the same time, the company's electric wheelchairs, mobility aids and other products will continue to realize independent production next year and expand production capacity.
With the help of the company's online and offline channel advantages, it is expected to achieve rapid growth in related categories
.
The domestic cryogenic storage giant Haier Biology has also attracted the attention of public funds
.
The company released a record sheet of investor relations activities on December 2 and accepted investigations from 64 institutions.
The institutions focused on the company's performance, overseas market conditions, and research and development systems
.
It is understood that Haier Bio-Bio has intensively received multiple batches of institutions since the disclosure of the 2021 third quarter report at the end of October.
From October 28 to mid-November, the company has disclosed 4 records of investor relations activities and the number of institutions received Nearly 300 companies, including many top public offerings such as E Fund, China Asset Management, and China Universal Fund, as well as many top private placements such as Gaoyi Assets and Kaifeng Investment
.
In November, the company got the attention of the industry due to the fact that more than 150 institutions got together in three days.
At that time, the institutions mainly focused on the company's Internet of Things solution business, overseas distribution network system construction, future planning and other main business development
.
Haier Biological, a biomedical cryogenic storage equipment giant, is currently committed to transforming into a biosafety solution provider
.
In addition, pharmaceutical companies such as Xianju Pharmaceutical, Jincheng Pharmaceutical, Panlong Pharmaceutical, and Yuekang Pharmaceutical have also received institutional surveys in the past week.
The number of surveyed institutions is 34 and 57 respectively
.
Among them, Xianju Pharmaceutical is a pharmaceutical company integrating raw materials and preparations.
The organization is very concerned about the impact of centralized procurement on the company’s future development.
The company stated in the research report that if the company’s products are included in centralized procurement, it will mainly be anesthetic muscle relaxation preparations.
The revenue side of the company will have an impact; the influence of the centralized procurement of cisatracurium has been reflected in the second quarter, and the company's cisatracurium API has been transformed from the original pure self-supplied to simultaneous external sales
.
The profit side is relatively controllable; Ropivacaine Hydrochloride Injection was shortlisted for the fifth batch of national centralized procurement, which is a good opportunity for the company, and its sales volume has shown a substantial increase; the application field of misoprostol tablets is small and specialized.
There are mainly three domestic manufacturers, and these three companies are also involved in centralized procurement.
The manufacturers are relatively fixed and the medications are stable
.
